US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Abivax SA - American Depositary Shares (NQ:ABVX)

88.22 -3.51 (-3.83%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Abivax Announces a Change to the Composition of its Board of Directors
From Abivax
Via GlobeNewswire
News headline image
This Veeva Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
From Abivax
Via GlobeNewswire
News headline image
Abivax presents third quarter 2024 key financial information
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
From Abivax
Via GlobeNewswire
News headline image
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
From Abivax
Via GlobeNewswire
News headline image
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
From Abivax
Via GlobeNewswire
News headline image
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
From Abivax
Via GlobeNewswire
News headline image
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
From Abivax
Via GlobeNewswire
News headline image
Abivax presents first-half 2024 financial results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
From Abivax
Via GlobeNewswire
News headline image
Abivax Provides Operational and Key Program Update
From Abivax
Via GlobeNewswire
News headline image
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
From Abivax
Via GlobeNewswire
News headline image
Earnings Scheduled For April 2, 2024 ↗
Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
Via ACCESSWIRE
News headline image
Cross-Border Logistics Provider Globavend Debuts In Quiet Week ↗
Shares of cross-border logistics provider Globavend opened for trading on Wednesday. A clinical-stage biotechnology company and an insurance company also opened up to close out another quiet week for... 
Via Talk Markets
News headline image
Webuy Shares Soar In Market Debut ↗
Shares of e-commerce retailer Webuy soared in their trading debut after the IPO was priced at the low end of the $4.00-$4.50 per share range. The company said it expects to use the proceeds for... 
Via Talk Markets
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 Next >